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Abstract: Immunotoxins are chimeric molecules that combine the specificity of an antibody to
recognize and bind tumor antigens with the potency of the enzymatic activity of a toxin, thus,
promoting the death of target cells. Among them, RNases-based immunotoxins have arisen as
promising antitumor therapeutic agents. In this work, we describe the production and purification of
two new immunoconjugates, based on RNase T1 and the fungal ribotoxin α-sarcin, with optimized
properties for tumor treatment due to the inclusion of a furin cleavage site. Circular dichroism
spectroscopy, ribonucleolytic activity studies, flow cytometry, fluorescence microscopy, and cell
viability assays were carried out for structural and in vitro functional characterization. Our results
confirm the enhanced antitumor efficiency showed by these furin-immunotoxin variants as a result of
an improved release of their toxic domain to the cytosol, favoring the accessibility of both ribonucleases
to their substrates. Overall, these results represent a step forward in the design of immunotoxins
with optimized properties for potential therapeutic application in vivo.
Keywords: immunotoxin; ribotoxin; α-sarcin; RNase T1; furin; intracellular trafficking; colorectal cancer
Key Contribution: This work not only represents a step forward in optimizing the cytotoxic
efficacy of immunotoxins based on RNase T1 and α-sarcin, but also highlights the development of
an immunotoxin design platform based on these ribonucleases.
1. Introduction
Due to their high cytotoxicity, specificity, and effectivity, immunotoxins have arisen as potent
and promising antitumor agents [1–3]. These chimeric proteins are composed of a target domain
that specifically targets a tumor marker, fused to a toxic domain, responsible for the cytotoxicity [4,5].
Their mechanism of action involves, in a first step, high affinity binding to the tumor antigen by the
targeting domain, followed by the internalization of the complex by endocytosis, and finally the release
of the toxic domain promoting the death of target cells [6–8]. Over the last years, multiple evidences have
been gathered demonstrating that the efficiency of immunotoxins depends on different aspects [9,10]
such as the following: antibody functional affinity and specificity for the tumor antigen expressed on
the cell surface, the complex internalization efficacy, the rate of the toxin release in its intracellular
route, and its intrinsic specificity and potency.
Toxins 2019, 11, 593; doi:10.3390/toxins11100593 www.mdpi.com/journal/toxins
Toxins 2019, 11, 593 2 of 20
Currently, most of the immunotoxins are designed as recombinant fusion proteins.
Different antibody fragments and linkers have been used. Thus, immunotoxins have been engineered
to achieve greater specificity and tumor labelling and enhanced antitumor efficacy by reducing size and
improving tumor penetration. Regarding this field, antibody engineering has pursued the development
of different new formats with improved properties that are being incorporated within immunotoxin
constructs [11–14]. Furthermore, beyond antibodies, other specific molecules, such as interleukins
and growth factors, have been employed as targeting domains, leading to the first FDA-approved
immunotoxins indicated for the treatment of acute myeloid leukemia [15] or hairy cell leukemia [16].
Toxins from different origins, have also been employed such as Pseudomonas exotoxin A, Diphteria
toxin, actinoporins, gelonin, and the plant toxin ricin, among others [17–26]. Interestingly, ribonucleases
(RNases) have acquired a significant importance due to their ideal features for being included as
immunotoxin toxic domains [27–32]. In particular, ribotoxins stand out within the family of extracellular
fungal RNases, as part of the toxic domain of immunotoxins, due to their small size, high thermostability
and resistance to proteases, poor immunogenicity, and especially because they are highly effective
to inactivate ribosomes [33–38]. As proven by the previous results obtained within α-sarcin-based
immunotoxins, α-sarcin arises as the most promising ribotoxin to be included in these antitumoral
therapeutic designs [36,38–40]. Its specific ribonucleolytic activity against just one single rRNA
phosphodiester bond, located at the sarcin-ricin loop (SRL) of the larger rRNA, causes protein
biosynthesis inhibition and apoptosis [41–43].
Few studies, however, have been focused on improving the effectiveness of immunotoxins by
modulating their intracellular pathway [44–46]. As a general mechanism, once the target domain
binds to the tumor antigen and gets internalized, the antigen-immunotoxin complex is found in the
early endosomes, where it can be later recycled and presented back into the cell membrane or finally
degraded into lysosomes. Toxin release and endosomal escape depends then on its intrinsic features.
The two main routes that are usually followed by toxins are the following: (1) the route via the Golgi
apparatus or (2) direct translocation to the cytosol [1]. Therefore, intracellular toxin trafficking can
be considered to be a key checkpoint for desired cytotoxic effects and regarding cytotoxic efficiency,
toxin delivery to the cytosol appears as a well-stablished rate-limiting step [1,47].
In this sense, we have previously produced and characterized two immunoconjugates, IMTXA33αS
and scFvA33T1, based in the ribotoxin α-sarcin or the nontoxic RNase T1, respectively, fused to the
variable domains (scFv) of the monoclonal antibody A33, which recognize and bind specifically the
tumor-associated antigen GPA33, overexpressed in most of colorectal cancers [30,36,48,49]. We have
characterized in detail both immunoRNases, not only for their structural and functional features,
but also as a model to evaluate the effect of the different toxic domains and the relationship between
intracellular trafficking and immunotoxins cytotoxicity [39,40].
Briefly, the antitumoral activity differences observed between both constructs have been
explained by two aspects. The exquisite specificity of the ribonucleolytic activity of α-sarcin against
ribosomes [36,40] in comparison with that exhibited by RNase T1 [30,50] and the intracellular pathway
followed by each toxic domain, being the latter extremely decisive [39]. On the one hand, regarding the
enzymatic properties of RNase T1, it is a much less specific acid cyclizing ribonuclease, with preference
for the hydrolysis of GpN bonds. Although it has the same catalytic mechanism as ribotoxins, the latter
present structural differences and small modifications in their catalytic residues that make them highly
specific in terms of their ribonucleolytic activity. On the other hand, α-sarcin release to the cytosol could
be carried out directly from endosomes or from the retrograde pathway involving Golgi apparatus,
due to its ability to interact with the acidic components of the endosomes and Golgi membranes.
Conversely, RNase T1, a nontoxic RNase, with an acidic isoelectric point value (pI), is not able to
interact with the acidic components of endosome or Golgi membranes. Therefore, its release into the
cytosol is impaired, favoring its degradation in the lysosomes or its accumulation into the late Golgi
apparatus (Figure 1) [39].
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family. Furin was known as the first mammalian proprotein-processing enzyme, exhibiting cleavage 
specificity for paired basic amino acid residues. Proteins were cleaved just downstream of the target 
sequence, canonically, Arg-X-(Arg/Lys)-Arg’, with a minimal recognition cleavage site, described as 
Arg-X-X-Arg [59,60]. 
Within this idea, in this work we describe the production, purification, and in vitro functional 
characterization of two colorectal antitumor immunoRNases, including a furin cleavage site, based 
in the fungal ribotoxin α-sarcin and RNaseT1, IMTXA33furαS and scFvA33furT1, respectively 
(Figure 2). It is noted that our immunotoxins are usually produced in the heterologous system P. 
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extracellular medium is driven by the α-factor signal peptide, which is finally released from the 
mature immunotoxin polypeptide chain by the action of Kex2 proteases. As furin belongs to this 
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Figure 1. Scheme of the intracellular route followed by IMTXA33αS and scFvA33T1. As previously
described [37], IMTXA33αS is internalized via early endosomes and follows the Golgi ap aratus
retrograde pathway, before -sarci release to the cytosol to exert its ribonucleolytic activity.
Once internalized, scFvA33T1 appears also in the Golgi apparatus but mainly it is driven to lysosomes.
These different pathways explain the more cytotoxic efficiency of IMTXA33αS.
In this context, some designs of immunotoxins with linkers including a specific furin cleavage
site have been shown to be more cytotoxic [51–54]. This observation would confirm that intracellular
processing and release of the toxic moiety is one of the key optimization spots for immunotoxin
design [55–57]. Furin is a transmembrane enzyme present in the plasma membrane, the endosomes,
and most notably in the trans-Golgi network [58]. It is a serine protease that belongs to the subtilisin
family. Furin was known as the first mammalian proprotein-processing enzyme, exhibiting cleavage
specificity for paired basic amino acid residues. Proteins were cleaved just downstream of the target
sequence, canonically, Arg-X-(Arg/Lys)-Arg’, with a minimal recognition cleavage site, described as
Arg-X-X-Arg [59,60].
Within this idea, in this work we describe the production, purification, and in vitro functional
characterization of two colorectal antitumor immunoRNases, including a furin cleavage site, based in
the fungal ribotoxin α-sarcin and RNaseT1, IMTXA33furαS and scFvA33furT1, respectively (Figure 2).
It is noted that our immunotoxins are usually produced in the heterologous system P. pastoris, a generally
regarded as safe (GRAS) organism [61]. Thus, the immunotoxin secretion to the extracellular medium
is driven by the α-factor signal peptide, which is finally released from the mature immunotoxin
polypeptide chain by the action of Kex2 proteases. As furin belongs to this family and exhibits some of
their recognition site characteristics, a minimum recognition sequence of furin has been used to avoid
recognition by the Kex2 protease present in P. pastoris [62].
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blot immunodetection, under reducing conditions, were carried out to analyze the identity and 
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IMTXA33furαS, respectively, corresponding to the expected theoretical molecular weight, were 
visualized by Coomassie blue staining and were also recognized by the anti-α-sarcin serum or 
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structural features of the domains that conform both immunoconjugates, and therefore compatible 
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2. Schemes showing both genetic a d domain structures of scFvA33-furin based immunotoxins.
(A) Diagrammatic representation of g ne construct. Both constructs include t e α-factor ig al peptid
for secreted expression in P. pastoris, the anti-GPA33 scFvA33 gene (VH-linker-VL), a furin cleavage sit
linker (black box), the toxic domain, and the six His-tag (hatc d box). The toxic domain was formed
by ribotoxin α-sarcin or RNase T1. (B) Schemat c model of the d main tructure of scFvA33-furin
based α-sarcin (upper) or RNase T1 (lower) immunotoxins.
2. Results
2.1. IMTXA33furαS and scFVA33furT1 Variants Were Purified as Fully Functional Immunoconjugates
Both IMTXA33furαS and scFVA33furT1 variants were successfully produced in the extracellular
media of P. pastoris cultures after 48 h of methanol induction. Then both immunoconjugates were
purified following dialysis and immobilized metal affinity chromatography (IMAC) (Figure 3A),
as described in the Methods section. SDS-PAGE and western blot immunodetection, under reducing
conditions, were carried out to analyze the identity and homogeneity of the purified proteins (Figure 3B).
Bands of 42 and 45 kDa for scFvA33furT1 and IMTXA33furαS, respectively, corresponding to the
expected theoretical molecular weight, were visualized by Coomassie blue staining and were also
recognized by the anti-α-sarcin serum or anti-His-tag antibody. The final purification yield for both
proteins was 1.5 and 3 mg per liter of induction medium for IMTXA33furαS and scFVA33furT1,
respectively. The far-UV CD spectra for both IMTXA33furαS and scFvA33furT1 were coherent with
those expected, according to the structural features of the domains that conform both immunoconjugates,
and therefore compatible with water-soluble globular functional proteins. In this sense, a high content
in beta sheet was observed that can be attributed to the folding described for the scFvA33, as well as to
the contribution of RNase T1 and α-sarcin native conformation, which also present a high content of
β-sheet and a small contribution of alpha helix [30,36] (Figure 3C).
To assess the correct functionality of these furin-variants immunoconjugates we first analyzed the
ribonucleolytic activity of the two RNases included in their toxic domains. As expected, IMTXA33furαS
was able to release the characteristic α-fragment, due to the specificity of its ribonucleolytic activity
against the rRNA sarcin-ricin loop (SRL) present in the ribosomes (Figure 4A). Regarding scFvA33furT1,
it exhibited nondistinguishable ribonucleolytic activity as compared with RNase T1 wild type or
scFvA33T1 immunoconjugate when assayed in zymogram analysis against its typical substrate, poly(G),
and in solution when Torula yeast RNA hydrolysis was measured (Figure 4B). The highly acidic feature
of RNase T1 and its smaller size as compared with the immunoRNase, might explain the different
intensities of the bands corresponding to scFvA33T1 and RNase T1. Thus, the incubations required
to perform the assay would allow it to leak out of the gel. Both assays revealed proper functionality
of the RNase moiety in the scFvA33furT1 variant. The ability of the targeting domain from both
immunoconjugates to bind GPA33-positive cells SW1222 was also evaluated. As determined by flow
cytometry results, both furin-variant constructs recognized GPA33-positive SW1222 cells (Figure 4C)
as efficiently as IMTXA33αS and scFvA33T1, used as controls.
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Figure 3. Production, purification, and structural characterization of furin-variant immunotoxins:
IMTXA33furαS (left) or scFvA33furT1 (right). In both cases: (A) SDS-PAGE analysis of aliquots taken
from IMAC performed to purify IMTXA33furαS or scFvA33furT1, visualized by Coomassie brilliant
blue staining. (B) Purified IMTXA33furαS or scFvA33furT1 final fraction detection by Coomassie
brilliant blue (left lane) or western blot (right lane). MW corresponds to prestained protein standards
(Bio-Rad). (C) Far-UV circular dichroism spectra (θMRW, mean residue weight ellipticities were
expressed as degree × cm2 × dmol−1) of: IMTXA33furαS (solid line) and IMTXA33αS (short dash line)
(left); scFvA33furT1 (solid line) and scFvA33T1 (short dash line) (right).
Moreover, both constructs showed high structural stability and also maintained their functional
integrity, when conditions mimicking a physiological context were assayed. In this sense, when purified
proteins were incubated in media for at least 72 h at 37 ◦C, far-UV CD spectra showed that the full
molecular folding of both immunotoxins were kept (Figure 5A,D). In addition, in the same conditions
and for at least 72 h, the specific ribonucleolytic activity of α-sarcin (Figure 5B) and the specific
antigen-binding ability of the target domain, in accordance with the flow cytometry analysis, were also
preserved (Figure 5C,E).
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Figure 4. Functional characterization: (A) RNase activity assay of purified IMTXA33furαS using rabbit
ribosomes as substrate. The characteristic α-fragment, as product of the specific RNase activity of
α-sarcin is shown (indicated by an arrow). For IMTXA33furαS, 2, 6, and 12 pmol were assayed and 12
pmol of IMTXA33αS were used as a control. (B) RNase activity assays of purified scFvA33furT1. Poly(G)
zymogram assay (upper panel) after SDS-PAGE of scFvA33furT1 or RNase T1. Four, 8 and 12 pmol of
protein were assayed. Colorless bands were a consequence of the RNase T1 unspecific ribonucleolytic
activity. MW (kDa), corresponds to electrophoretic molecular mass markers. Yeast RNA degradation
assay (lower panel): The graph represents the A260 values versus the different amounts of scFvA33furT1
(black circles), scFvA33T1 (open circles), and RNase T1 (triangles) assayed. (C) Flow cytometry analysis
of scFvA33furT1 (plot 2), scFvA33T1 (plot 3), IMTXA33furαS (plot 4), and (IMTXA33αS (plot 5) binding
to SW1222 (GPA33-positive cells). The control curve (plot 1) corresponds to cells just treated with the
anti-Histag-Alexa 488 antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
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with protein at 0.15 mg/mL in RPMI 1640 medium. (B) Specific ribonucleolytic activity against rabbit 
ribosomes. Samples were previously incubated at 37 °C in the absence of the substrate. The 
appearance of the α-fragment was indicated by an arrow. IMTXA33αS and α-sarcin wild type were 
used as controls. In all cases, 6 pmol of protein were assayed. (C,E) Binding assay o GPA33-positive 
SW1222 cells by flow cytometry analysis. Control curves (as in Figure 4). 
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antigen-specific binding capacity, as well as their ribonucleolytic activities, the next step was to 
analyze the effect of the furin cleavage site on the intracellular pathway followed after their 
internalization. In order to study this aspect, first the new constructs were labeled with Alexa 555. 
Both modified proteins remained fully structured, in comparison with the unlabeled versions 
(Figure S1), according to their far-UV CD spectra. 
Internalization and intracellular localization of both labeled constructs were then studied. As 
shown for IMTXA33furαS (Figure 6A) and scFvA33furT1 (Figure 6B), very low colocalization was 
observed for both immunoconjugates with early endosomes. Although, no substantial differences 
were found between both constructs, interestingly, IMTXA33furαS colocalization was detected at 
shorter incubation times, 20 min or 2 h, than that observed for scFvA33furT1, at 5 or 24 h. 
Figure 5. Stability assays of IMTXA33furαS (A–C) and scFvA33furT1 (D–E): In all cases, samples
were previously incubated at 37 ◦C for 0, 24, 48, and 72 h. (A,D) Far-UV circular dichroism spectra
(θMRW, mean residue weight ellipticities were expressed as degree × cm2 × dmol−1). Spectra were made
with protein at 0.15 mg/mL in RPMI 1640 medium. (B) Specific ribonucleolytic activity against rabbit
ribosomes. Samples were previously incubated at 37 ◦C in the absence of the substrate. The appearance
of the α-fragment was indicated by an arrow. IMTXA33αS and α-sarcin wild type were used as controls.
In all cases, 6 pmol of protein were assayed. (C,E) Binding assay o GPA33-positive SW1222 cells by
flow cytometry analysis. Control curves (as in Figure 4).
2.2. IMTXA33furαS and scFVA33furT1 Follow Different Intracellular Pathway
Once it was established that the new immunoconjugate variants kept intact their antigen-specific
binding capacity, as well as their ribonucleolytic activities, the next step was to analyze the effect of the
furin cleavage site on the intracellular pathway followed after their internalization. In order to study
this aspect, first the new constructs were labeled with Alexa 555. Both modified proteins remained
fully structured, in comparison with the unlabeled versions (Figure S1), according to their far-UV
CD spectra.
Internalization and intracellular localization of both labeled constructs were then studied.
As shown for IMTXA33furαS (Figure 6A) and scFvA33furT1 (Figure 6B), very low colocalization was
observed for both immunoconjugates with early endosomes. Although, no substantial differences were
found between both constructs, interestingly, IMTXA33furαS colocalization was detected at shorter
incubation times, 20 min or 2 h, than that observed for scFvA33furT1, at 5 or 24 h.
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plus GAM-Alexa 647 (blue), early endosomes were visualized with anti-EEA1 plus GAR-Alexa 488 
(green), IMTXA33furαS-555 or scFvA33furT1-555 (red). The appearance of yellow dots indicates 
colocalization with endosomes, while violet dots correspond to colocalization with the plasmatic 
membrane. 
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Golgi-apparatus. On the one hand, for IMTXA33furαS, partial colocalization degree (22%, overlap 
coefficient) with Golgi apparatus at 4 h was observed, remaining at similar levels after 16 h of 
incubation (18%) (Figure 7A). However, colocalization with lysosomes was almost negligible. On the 
other hand, taken into account that for RNase T1-based immunoconjugates a significant 
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scFvA33furT1 was measured. In this case, a significant colocalization was observed at 4 h, with 
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were treated with the antibiotic bafimolycin (<1%) (Figure 7B). 
Figure 6. Endosomes colocalization analysis: Immunofluorescence confocal microscopy images
obtained from cells incubated with IMTXA33furαS-555 and scFvA33furT1-555. Immunofluorescence
confocal microscopy images of SW1222 cells after incubation for 20 min, 2 h, 5 h, or 24 h (from left to
right) with IMTXA33furαS-555 (A) or scFvA33furT1-Alexa 555 (B). In all cases, images correspond to
merging of nuclei labeled with DAPI (grey), plasmatic membrane were visualized with anti-CD44 plus
GAM-Alexa 647 (blue), early endosomes were visualized with anti-EEA1 plus GAR-Alexa 488 (green),
IMTXA33furαS-555 or scFvA33furT1-555 (red). The appearance of yellow dots indicates colocalization
with endosomes, while violet dots correspond to colocalization with the plasmatic membrane.
As previously described for IMTXA33αS and scFvA33T1, two main intracellular pathways
are followed by the toxic domain once the endosomes have been reached, via lysosomes or via
Golgi-ap aratus. On the one hand, for IMTXA33furαS, partial colocalization degree (22%, overlap
coefficient) with Golgi apparatus at 4 h was observed, remaining at similar levels after 16 h of incubation
(18%) (Figure 7A). However, colocalization with lysosomes was almost negligible. On the other hand,
taken into account that for RNase T1-based immunoconjugates a significant colocalization with
lysosomes was previously described [39], lysosome colocalization for scFvA33furT1 was measured.
In this case, a significant colocalization was observed at 4 h, with degrees of 84%, but was dramatically
decreased after 16 h (23%), and nearly disappeare when cells were treated with the antibiotic
bafimolycin (<1%) (Figure 7B).
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Figure 7. Golgi apparatus and lysosomes colocalization analysis: Immunofluorescence confocal microscopy
images obtained from cells incubated with IMTXA33furαS-Alexa-555 (A) or scFvA33furT1-Alexa-555 (B).
(A) SW1222 cells were incubated for 4 or 16 h with both immunoconjugates as indicated in the figure.
In all cases, images correspond to merging of nuclei labeled with DAPI (grey), Golgi with agglutinin or
lysosomes with Lysotracker (red) and IMTXA33furαS-555 or scFvA33furT1-555 (green). (B) In the case of
scFvA33T1-555, incubation was also made adding bafilomycin at 5 ng·mL−1. Quantitative colocalization
analysis was made as indicated in Methods. The appearance of yellow dots indicates colocalization with
Golgi (A) or lysosomes (B).
The results obtained with the furin variants, compared to those described previously for the
original constructions, show significant differences in the degree of colocalization with the cellular
organelles involved in their intracellular pathways. On the one hand, in the case of IMTXA33furαS,
although it follows the endosomas-Golgi route, just like the original construct [39], its detection in
endosomes and Golgi apparatus is significantly lower, suggesting a greater or better release to the
cytosol. On the other hand, for scFvA33furT1, there is a very significant increase in colocalization with
the Golgi and a decrease in the case of lysosomes. As later discussed, these results would suggest
that the presence of the furin cleavage site facilitates the release to the cytosol of the toxic domain of
both immunoconjugates.
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2.3. The Presence of the Furin Cleavage Site Significantly Increases the Cytotoxicity of Both Immunoconjugates
In vitro cytotoxicity assays were performed, to assess the effect of furin cleavage at the specific site
included in these new designs. IMTXA33furαS showed an enhanced cytotoxicity with an IC50 two-times
lower than that described for IMTXA33αS (Figure 8A). Even more interesting, cytotoxicity was increased
by an additional three times when brefeldin A, that causes disassembly of Golgi-apparatus, was added
(Figure 8A). However, the addition of bafilomycin that inhibits lysosomal acidification, resulted in no
change in the cytotoxicity of this construction (data not shown). On the other hand, scFvA33furT1
toxicity was increased up to three times as compared to that described for scFvA33T1, being even
greater when bafilomycin was added (Figure 8B). In this case no significant effect was observed with
brefeldin A (data not shown).
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Figure 8. Cytotoxic characterization of IMTXA33furαS (A) and scFvA33furT1 (B). (A) Protein
biosynthesis inhibition assay. SW1222 cells were incubated for 72 h with IMTXA33αS (), IMTXA33furαS
(H), and IMTXA33aS + brefeldin A (#). (B) MTT viability assay of SW1222 cells incubated for 72 h
with scFvA33T1 (), scFvA33furT1 (H), and scFvA33furT1+ bafilomycin (∆). The 50% level of protein
biosynthesis inhibition or cell viability were indicated (dashed line).
3. Discussion
We have purified and characterized two new optimized immunoconjugates, IMTXA33furαS and
scFvA33furT1, which include a specific cleavage site for furin in the linker between the targeting
and toxic domains of both constructs. They were purified to homogeneity from P. pastoris cultures,
showing the expected size and folding, according to their biophysical characterization. This structural
Toxins 2019, 11, 593 11 of 20
characterization yielded results which were consistent with the features previously described for
their original counterparts, IMTXA33αS and scFvA33T1 [30,36], results that also were fully consistent,
regarding to the nature and content of the secondary structure elements described for α-sarcin,
RNase T1, and A33 scFv, their native domains [63–67]. Both constructs were also able to specifically
bind to GPA33 expressed on the surface of the membrane and be internalized into SW1222 colorectal
cancer cells, indicating that the targeting domain was fully functional.
Furthermore, they kept the original α-sarcin and RNase T1 ribonucleolytic activities, needed for
ribosome inactivation and RNA hydrolysis, respectively. Moreover, when physiological-like conditions
were analyzed, both IMTXA33αS and scFvA33T1, were stable and functional. In this sense, we could
conclude that both immunoconjugates were correctly folded in terms of their structural and functional
features, at least to the same extent as their original designs, IMTXA33αS and scFvA33T1.
As mentioned before, there is a close relationship between the intracellular route followed by
the proteins included in the toxic domains of immunoconjugates and the antitumor efficiency of the
immunotoxins [1]. Accordingly, this relationship had been previously reported for IMTXA33αS and
scFvA33T1 [39]. Thus, once internalized, IMTXA33αS mainly followed the endosome-Golgi-apparatus
network, whereas scFvA33T1 appeared indistinctly distributed between the lysosomes and the
Golgi-apparatus. It is precisely this difference in the internalization pathway followed that led to a
greater cytotoxic efficiency of IMTXA33αS [39].
Different designs of immunotoxins have been described including linkers with a furin cleavage site
showing an increase in cytotoxic efficacy [51–54], confirming that intracellular processing and release
of the toxic moiety is one of the key optimization spots in immunotoxin design [55–57]. Within this
context, the main purpose driving this work was to evaluate the effect of including a furin linker in
the previously characterized α-sarcin- and RNaseT1-based immunoconjugates [30,36,39]. The starting
hypothesis was that this protease-specific site would ease the toxic moieties release and, consequently,
would improve the cytotoxic efficiency of IMTXA33furαS and scFvA33furT1. Quite surprisingly,
and although the results obtained for both constructs confirmed the preferred intracellular route used
by each of the constructs [39], they, nevertheless, showed significant differences from what had been
described for their parental designs.
The results herein presented further confirm that the cytotoxic mechanism of α-sarcin-based
immunotoxins, IMTXA33furαS and IMTXA33αS, involves the endosome-Golgi intracellular pathway.
The differences observed between both immunotoxins concerning the colocalization rate with the Golgi
apparatus are in good agreement with their cytotoxic efficiency (Table 1). IMTXA33furαS cytotoxicity
was two-fold higher than that observed for IMTXA33αS. Interestingly, the furin variant and its parent
counterpart exhibited completely different behavior when traffic through the Golgi was blocked by
the addition of brefeldin A. Whereas in the case of the original immunotoxin its cytotoxicity was
dramatically reduced as an effect of brefeldin A, for the furin variant the cytotoxicity was significantly
increased. These differences can only be explained by the presence of the furin cleavage site in the
design of the immunotoxin. Furin protease activity would produce an increase in the amount of free
α-sarcin that can interact with endosomal membranes and thus be released more efficiently to the
cytosol, even without reaching the Golgi apparatus. It has been proven a long time ago that wild-type
α-sarcin has the ability to translocate across a lipid bilayer rich in negatively charged phospholipids [68].
However, in the case of the original immunotoxin, most of the chimeric protein would reach the
Golgi, and therefore the action of brefeldin A would negatively affect the release of the toxin. It must
be emphasized that the inner membranes from both endosomes and Golgi apparatus have a high
content of negative charges [69–72], contributing to α-sarcin translocation to the cytosol directly from
endosomes or from Golgi apparatus [42,43]. Moreover, furin exert its protease activity not only in the
Golgi but also in the endosomes [58]. Thus, α-sarcin release to the cytosol is facilitated by the presence
of the furin cleavage site.
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Table 1. Comparison of the results obtained for the furin variants vs. their originals counterparts, in
relation to: level of colocalization with the Golgi apparatus and lysosomes; as well as the IC50 values
obtained in the different cytotoxicity assays performed with just IMTXA33furαS or scFvA33furT1, or
adding bafilomycin or brefeldin A, as described in Figure 8.
IMTXA33furαS IMTXA33αS *
Golgi colocalizationOverlap
coefficient at 16 h (%) 18.2 46.3
IC50 (nM) 15 30–40
IC50 (nM) + Bafilomycin 15–20 30
IC50 (nM) + Brefefeldin A 5 >500
IMTXA33furT1 IMTXA33T1 *
Lysosomes colocalizationOverlap
coefficient at 16 h (%) 23.4 58.1
IC50 (nM) 300 >1 mM
IC50 (nM) + Bafilomycin 70–90 70–90
IC50 (nM) + Brefefeldin A 300 >1 mM
* Data from IMTXA33αS and scFVA33T1 used for comparison [39].
For scFvA33furT1, significant enhanced cytotoxicity was also observed when compared to the
original design, scFvA33T1. As observed in the internalization assays, the degree of colocalization with
lysosomes was significantly lower when compared to that previously described for scFVA33T1 [39]
(Table 1), suggesting that most of scFvA33fur1 could follow the Golgi pathway or that the inclusion
of the furin cleavage site would again favor its accumulation in endosomes. Within this, addition of
bafilomycin, which impaired the recycling in the lysosomes, produced and increased in the cytotoxic
effectiveness. However, the best IC50 value obtained for scFvA33furT1 (70–90 nM) after incubation
with bafilomycin did not improve the cytotoxic effectiveness obtained by its original equivalent in
the presence of the same antibiotic. Regarding this, it must be noted that the acidic pI value of RNase
T1 [50,73] hamper its interaction with the endosome or Golgi membranes. Even if the lysosome
pathway was partially blocked, the release into the cytosol was impaired. In fact, there is not any
published account of RNase T1 being able to translocate a biological membrane on its own.
In summary, our results confirm the different routes followed by α-sarcin and RNaseT1 when
included as part of the toxic domain of an immunotoxin and how we can take advantage of their
features including a furin cleavage site in its design. Both furin-variant immunoconjugates exhibit
enhanced antitumor effectiveness than that described for their original parents. Therefore, in vivo
assays with IMTXA33furαS, exhibiting increased antitumor activity than that based in RNase T1,
must be addressed.
4. Conclusions
This work not only represents a step forward in optimizing the cytotoxic efficacy of immunotoxins
based on α-sarcin and RNase T1, but also highlights the development of an immunotoxin
design platform based on these ribonucleases, including new designs with different specificities,
with monomeric or trimeric formats [74,75], or including the use of non-immunogenic variants of
α-sarcin [38]. The combination of all these optimization approaches will represent a very important
boost for its application in the clinic.
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5. Materials and Methods
5.1. Plasmid Design
Plasmids encoding IMTXA33αS and scFvA33T1 were previously obtained [30,36]. PCR was used
to amplify the cDNA sequences of interest, using the necessary oligos to incorporate the sequence
coding for the furin cleavage site between the target and the toxic domains, and also the restriction
sites needed for cloning. Once purified, the resultant IMTXA33furαS and scFvA33furT1 cDNAs
were cloned in pPICZαA (Invitrogen), for their expression in the methylotrophic yeast P. pastoris
KM71. To facilitate protein detection and purification, as in their original counterparts, a 6 His-tag was
included at the C-terminus of both immunotoxins (Figure 2). The expression vectors were amplified
in E. coli DH5αF’ and subsequently sequenced, using the DNA sequencing service of Universidad
Complutense’s Genomics Unit.
5.2. Protein Production and Purification
Electrocompetent P. pastoris KM71 cells were used to electroporate 5–10 µg of the corresponding
linearized plasmid previously cleaved with Pme I. A Bio-Rad Gene pulser apparatus (Bio-Rad, Berkeley,
CA, USA) was used for this purpose. Multiple independent clones were selected with different amounts
of zeocin (100, 400, or 750 µg/mL) and assayed to find the most productive colonies. To carry out these
screenings, cells were grown in BMGY in 24-well plates at 30 ◦C for 24 h, were harvested afterwards,
and finally suspended in BMMY. For induction of protein production, the cuture was shaked at 25 ◦C
and 200 rpm, as previously described [30,36,39].
Once the induction was completed, the secretion to the extracellular media of the proteins of
interest was analyzed by 0.1% (w/v) sodium dodecyl sulfate (SDS)-15% (w/v) polyacrylamide gel
electrophoresis (PAGE) and western blot. In this sense, for the specific detection of the toxic domain by
western blot, a rabbit anti-α-sarcin serum was used. In addition, an anti-histidine tag antibody was
used to check integrity of the purified proteins. Large-scale production of both immunotoxins was
carried out by addition of 25 mL of preinoculum to a 2 L baffled flasks containing 350 mL of BMGY.
Then the culture was incubated with shaking for 16 h at 30 ◦C and 220 rpm. Cells were recollected by
soft centrifugation at room temperature and resuspended again in 200 mL of BMMY. For induction
of protein production, cells were incubated at 25 ◦C, 250 rpm shaking, for 48 h, supplementing the
culture with methanol every 24 h. Once finalized, dialysis of the extracellular medium containing the
proteins of interest was carried out, using a 50 mM sodium phosphate buffer with 0.1 M NaCl, pH 7.5.
IMTXA33furαS and scFvA33furT1 were purified from the dialyzed extracellular medium by
IMAC. A Ni2+-NTA agarose column was used for this purpose (HisTrap™ FF Columns, GE Healthcare,
Fairfield, CT, USA). The extracellular media was applied to the column at 1 mL/min. The flow rate was
controlled by a peristaltic pump. Two consecutive washes were done with the dialysis buffer and with
the same but adding 20 mM imidazole, before elution of the proteins of interest, by using the same
buffer but containing 250 mM imidazole. Finally, the different aliquots containing the purified proteins
were collected and dialyzed again against the dialysis buffer.
5.3. Biophysical Characterization
Absorbance measurements were performed on an Uvikon 930 spectrophotometer (Kontron).
As described before [76], far-UV circular dichroism (CD) spectra were carried out using a Jasco 715
spectropolarimeter. Proteins dissolved in PBS were prepared at 0.15 mg/mL. Cells of 0.1 cm optical
path were used. Four spectra were averaged to obtain the final data. For stability assays, spectra were
obtained after previous incubation of both constructs at 37 ◦C for 0, 24, 36, 48, or 72h in RPMI 1640.
5.4. Ribonucleolytic Activity Assays
The specific ribonucleolytic activity of α-sarcin, included in the toxic domain of IMTXA33furαS,
was followed as described before [73,77]. For detection of the release of the characteristic 400 nt
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rRNA, namely α-fragment, we used as substrate ribosomes from a rabbit cell-free reticulocyte lysate.
Briefly, the lysate was diluted three-fold in 40 mM Tris-HCl buffer, pH 7.5, containing 40 mM KCl and
10 mM EDTA. Then, 50 µL aliquots were taken of this dilution (5–6 pmol of ribosomes approximately)
and incubated for 15 min at room temperature with different amounts of the proteins to be assayed.
Then, the reaction was finished by adding 250 µL of 50 mM Tris-HCl, pH 7.4, 0.5% (w/v) SDS, followed
by briefly vortex. Subsequently, RNA phenol/chloroform extraction was carried out. The RNA pellet
obtained by the addition of isopropanol to the aqueous phase, was then washed with 70% (v/v) ethanol,
dried exhaustively, and finally resuspended in 10 µL of DEPC H2O. The presence of α-fragment in the
samples was detected by ethidium bromide staining after electrophoresis, on denaturing 2% agarose
gels. For quantification of the bands we used the Gel Doc XR Imaging System and Quantity One 1-D
analysis software (Bio-Rad, Berkeley, CA, USA). Original IMTXA33αS [36] was used as the control.
The ribonucleolytic activity of RNase T1, included in scFvA33furT1, was analyzed by two
parallel assays. First, RNA degradation in solution was tested by measurement of Torula yeast RNA
(Sigma, type VI; Sigma-aldrich, St. Louis, MI, USA) hydrolysis [73]. In this assay the absorbance values
obtained are proportional to the amount of soluble small oligonucleotides resulting from the RNasa
activity on RNA larger size fragments contained in the substrate sample. The results obtained for
the RNA samples analyzed (2 mg/mL) without protein were used to consider nonenzymatic RNA
degradation, while original scFvA33T1 [30] and free RNase T1 were used as controls. In the second
assay, the activity of purified scFvA33furT1 and RNase T1 was evaluated following the zymogram
method [78]. Briefly, samples were applied into SDS-PAGE in 15% polyacrylamide gels, containing 0.1%
(w/v) SDS and embedded with 0.3 mg/mL poly(G) homopolyribonucleotide [79]. Proteins exhibiting
RNase activity were visualized as colorless bands, whereas the rest of the gel appeared colored.
5.5. Cell Lines Culture
Colon carcinoma SW1222 cells were used as model for the GPA33-positive cellular line [30,36,39].
The cultures were grown as described [30], in RPMI 1640 medium (Sigma-aldrich, St. Louis, MI,
USA), supplemented with glutamine (300 mg/mL), containing 50 U/mL of penicillin and 50 mg/mL of
streptomycin. Finally, the media was supplemented with 10% fetal bovine serum (FBS). Incubation of
the cells was carried out at 37 ◦C in a humidified atmosphere (CO2:air, 1:19, v:v). Trypsinization was
routinely done for harvesting and propagation of the cultures. A hemocytometer was used to count
the cells used in all assays described.
5.6. Flow Cytometry Studies
Trypsinized cells were distributed into different aliquots, containing 3 x 105 cells/mL, and washed
several times with PBS 0.1% (w/v) BSA containing 0.02% (w/v) sodium azide. The samples were incubated
with gentle shaking for 1 h at room temperature, with 1 µM of IMTXA33furαS or scFvA33furT1,
using their original counterparts as positive controls. A second incubation, adding anti-His-Alexa488
(Sigma-aldrich, St. Louis, MI, USA) diluted 1/100, was carried out in the dark. When necessary, between
the different steps, cells were collected by centrifugation (1200× g, 4 ◦C, 10 min) and then washed
with PBS for several times. Flow cytometry acquisition was done on a FACScan (Becton Dickinson,
Becton Dickinson, NJ, USA) and data were obtained using the WinMDI software. For stability assays,
IMTXA33furαS and scFvA33furT1 were previously incubated at 37 ◦C for different times (0, 24 or 72 h).
5.7. Fluorescence Microscopy
To carry out these assays, both immunotoxins were first labeled. As previously described [37],
using the Alexa Fluor 555 Protein Labeling Kit (Invitrogen, Carlsbad, CA, USA). Both labeled conjugates
(IMTXA33furαS-555 and scFvA33furT1-555) were purified and characterized to ensure the preservation
of their structural and functional features.
SW1222 cells were first trypsinized, seeded at 8 × 105 cells/well using cover-glasses, and incubated
overnight at 37 ◦C. For treatment, IMTXA33furαS-555 or scFvA33furT1-555, at 25 µg/mL, were added
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to cells for the following different periods of time: from 20 min to 24 h for endosomes colocalization
assays, and 4 or 16 h when lysosomes/Golgi colocalization assays were performed. Confirmation of
colocalization with lysosomes was also studied by the addition of bafilomycin at 5 ng/mL, an antibiotic
that inhibits lysosomal acidification [80], in combination with the immunoRNase. To observe the
plasmatic membrane, incubation with anti-CD44 mAb [81] were performed. After removing the
medium, the cells were fixed for 15 min with PBS containing 3% (v/v) p-formaldehyde and incubated
for 15 min in PBS containing 50 mM ammonium chloride. Cells were permeabilized by the addition of
digitonine at 0.01% (w/v) in PBS and incubation for 30 min, followed by another incubation in PBS
containing 1.0% (w/v) BSA for 1 h. Different probes were used for organelle labeling as follows: an Ab
targeting protein EAA1, present in the early endosomes [82]; lysosomes were labeled with Lysotracker
(Life Technologies, Carlsbad, CA, USA), a fluorescence acidotropic specific probe [83]; and Golgi
apparatus with Wheat Germ Agglutinin (Life Technologies) that binds to the highly abundant sialic
acid present in the Golgi membranes [84]. Donkey anti-mouse Alexa 647 (DAM-Alexa 647) or goat
anti-rabbit Alexa 488 (GAR-Alexa 488) were also added as secondary antibodies. For nuclei labeling,
10 µL of Prolong Gold-DAPI (Life Technologies) were added. Incubations were carried out at room
temperature and the final samples were kept at 4 ◦C. To obtain the corresponding images, a Leica TCS
SP2 confocal microscope was used, followed by analysis with the LCS lite software. Images presented
correspond to the optical planes concerning the internal content of the cells selected for analysis.
For each sample, ten different images were taken along the Z-axis, covering all the cells, from the
basal zone to the apical one, Images shown correspond to the internal content of the cells, in particular
to slices 4 to 6. ImageJ software was used to performed colocalization quantification, using two
coefficients, the Pearson’s correlation coefficient and, as described by Mander, the overlap coefficient.
Both coefficients referred to the correlation between the intensity distribution of the channels and the
true degree of colocalization, respectively [85].
5.8. MTT Viability Assay
Cell viability was evaluated by using the MTT-Cell Proliferation Kit I (Roche, Basel, Switzerland)
as previously described [30,39]. Briefly, 5 × 103 trypsinized cells/well were seeded and then incubated
for 24 h at 37 ◦C. The medium was then removed and scFvA33furT1 or scFvA33T1 were added at
different concentrations in 200 µL final volume. Samples where incubated for 96 h, followed by
another incubation with MTT at 0.5 mg/mL during 4 h at 37 ◦C. Finally, the solubilization buffer was
added and the viability was determined in terms of A595 nm, whereas the higher A595 values were in
correspondence with increasing amounts of viable cells. Cells incubated only with medium, in the
absence of the protein, were taken as 100% viability. If necessary, samples including bafilomycin at
5 ng/mL, together with the protein were also done. Control only with bafilomycin, was included
to evaluate potential drug related toxicity. The results shown correspond to the average of four
independent assays.
5.9. Protein Biosynthesis Inhibition
To evaluate the cytotoxicity of ribotoxins the protein biosynthesis inhibition assay is routinely
used [41–43]. Briefly, cells were seeded into 96-well plates (1× 104 cells/well) in culture medium and kept
under standard culture conditions for 24 h. Different concentrations of the different immunoconjugates,
in 200 µL of free-FBS fresh medium were added to the cells. After 72 h of incubation at 37 ◦C,
the medium was removed, followed by replacement with a fresh one containing 1 mCi per well of
L-[4-C-3H]-Leucine (166 Ci/mmol; GE Healthcare, Fairfield, CT, USA). The samples were incubated
again for 6 h, the medium was eliminated, and cells were then fixed with 5.0% (w/v) trichloroacetic
acid. Several washed with cold ethanol were done, before the pellet was finally dissolved in 200 µL of
0.1 M NaOH containing 0.1% SDS. A Beckman LS3801 liquid scintillation counter was used to measure
its radioactivity. Cytotoxicity was calculated in terms of IC50 values (namely, protein concentration
needed to produce 50% protein synthesis inhibition), expressed as the percentage of the radioactivity
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incorporated in the assay. Three independent replicates per two assays were performed to average
the IC50 values. When required, brefeldin A, that causes disassembly of Golgi-apparatus by altering
vesicular trafficking [86], was added at 1 ng/mL together with the immunotoxins. A control, just with
brefeldin A without the proteins, was performed to evaluate drug related toxicity.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/11/10/593/s1,
Figure S1: Structural characterization of Alexa-555 labelled furin-variant immunotoxins.
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